Trump Deal Cuts Ozempic Prices

Novo Nordisk has announced a significant reduction in the prices of its popular medications, Ozempic and Wegovy. This move comes in the wake of a recent agreement involving President Donald Trump. The initiative aims to make these vital drugs more affordable for many Americans.

Trump Deal Cuts Ozempic Prices

As part of the deal, the direct-to-consumer monthly price for both Ozempic and Wegovy has been lowered to $349 from $499. Additionally, new cash-paying patients can purchase the two lowest dosages of either medication for just $199 per month for the first two months.

Details of the Price Reductions

• Monthly cost of Ozempic and Wegovy adjusted to $349.
• New patients can access intro pricing of $199 for the first two months.
• Cash-pay cost for the highest dose of Ozempic remains at $499 monthly.

In a statement, Dave Moore, Novo Nordisk’s executive vice president of U.S. operations, emphasized the company’s commitment to ensuring that its medications are “affordable and accessible to those who need them.”

Impact on Market Competition

This pricing structure aligns with Eli Lilly’s Zepbound, which is priced at $349 for its lowest dosage. The agreement not only benefits consumers but also positions these companies competitively in the weight loss and diabetes treatment market.

Long-term Cost Reductions Under Medicare

Furthermore, the deal aims to reduce Medicare costs for these GLP-1 treatments, which can previously reach up to $1,350 per month without insurance. Under the new structure, Medicare will pay just $245 per month for these essential medications.

• Monthly Medicare payment for GLP-1 treatments cut to $245.
• Potential patient payments of $350 monthly through TrumpRx.gov.
• Plans to further reduce costs to $250 per month within two years.

Additionally, a monthly price of $149 for the lowest dose of pill-form versions will be made available to both consumers and Medicare beneficiaries when they become available.

Access for Patients with Severe Obesity

Patients classified with severe obesity will soon gain access to these treatments through Medicare. A nominal co-pay of $50 will be required, starting as early as mid-2026, enhancing coverage for those most in need.

Despite these changes, Novo Nordisk’s stock prices remained stable, while Eli Lilly experienced a slight decline of 0.2%. This development marks a significant step towards more accessible diabetes and weight management treatments in the United States.